证券代码：300639 证券简称：凯普生物 公告编号：2025-032 广东凯普生物科技股份有限公司 关于公司及子公司获得发明专利授权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 广东凯普生物科技股份有限公司（以下简称"凯普生物"或"公司"）以及子公司 在 2025 年 4 月获得发明专利授权情况如下： | 序号 | 发明专利名称 | 专利号 | 专利类型 | 授予国家/地区 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 一种从孕妇宫颈脱 | | | | 广州凯普医药科 | | | 落细胞中分离胎盘 | HK40090275 | 发明专利 | 中国香港 | 技有限公司、凯 | | | 滋养层细胞的方法 | | | | 普生物 | | 2 | 一种从孕妇宫颈脱 | | | | 广州凯普医药科 | | | 落细胞中分离胎盘 | IDP000096677 | 发明专利 | 印尼 | 技有限公司、凯 | | | 滋养层细胞的方法 | | | | 普生物 | | 3 | 一种引物组合物及 | 202 ...

Core Insights - The company reported a significant decline in revenue and increased net losses for the year 2024, primarily due to the impact of centralized procurement policies on its HPV-DNA testing products and medical testing services [2][5] Financial Performance - The company achieved a revenue of 815 million yuan in 2024, representing a year-on-year decrease of 26.16% [2] - The net loss attributable to shareholders was 655 million yuan, a substantial increase of 566.20% compared to the previous year [2] - The non-recurring net loss was 660 million yuan, reflecting a decrease of 682.84% year-on-year [2] - Basic earnings per share were reported at -1.02 yuan [2] Business Segments - The molecular diagnostics segment generated revenue of 568 million yuan, down 20% year-on-year, accounting for 69.7% of total revenue [5] - The HPV testing sales volume was approximately 9 million units, with cumulative usage exceeding 75 million [5] - The medical testing services segment reported revenue of 241 million yuan, a decline of 38.48%, contributing 29.57% to total revenue [5] Financial Structure - Total assets decreased by 19.26% to 4.622 billion yuan, with accounts receivable at 1.094 billion yuan, down 42% year-on-year [5] - Total liabilities stood at 576 million yuan, resulting in a debt-to-asset ratio of 14.47% [5] - The net cash flow from operating activities was 79 million yuan, a decrease of 75.35% year-on-year [5] - The weighted average return on equity was reported at -14.62% [5] Research and Development - The company invested 102 million yuan in R&D, representing 12.57% of its revenue [5] - It obtained 6 new Class III medical device registrations and 30 domestic and international patents, bringing the total to 192 patents [5] - New products launched included cervical cancer methylation detection reagents and fully automated nucleic acid detection systems, aimed at enhancing tumor early screening and detection automation [5]

Summary of Cap Bio's Conference Call Company Overview - **Company**: Cap Bio - **Year**: 2024 - **Revenue**: 815 million yuan, a year-on-year decrease of 26.16% [3] - **Net Loss**: 660 million yuan, a year-on-year decline of 682% [3] Key Points Industry Impact - **HPV Procurement Impact**: The HPV centralized procurement led to a revenue decrease of approximately 100 million yuan, significantly affecting the company's income [2][5] - **Medical Testing Services**: The medical testing services segment faced challenges, with revenue of 241 million yuan, a year-on-year decline of 38.48%, but a 5% increase when excluding COVID-19 factors [3][6] Financial Performance - **Initial Losses**: The company reported initial losses of about 20 million yuan from the Chaozhou Kanghe Hospital due to high operational costs [2][7] - **Credit Impairment**: The company recorded a credit impairment and asset impairment of 640 million yuan [4] Strategic Adjustments - **Shift in Focus**: The company is shifting from less advantageous routine testing platforms to high-end specialized testing projects, such as molecular sequencing and mass spectrometry, with personnel adjustments to enhance operational efficiency [2][6][20] - **New Product Development**: Progress in promoting new products related to birth defects and personalized medicine, with the "Four Great Kings" series generating over 100 million yuan in revenue [3][10] Future Outlook - **Recovery Expectations**: The company anticipates a recovery in revenue by the third quarter of 2025, as the impact of HPV procurement is expected to bottom out [2][11] - **Healthcare Expansion**: Plans to establish a tumor early screening center and expand into the Guangdong East market, with profitability expected in the next one to two years [2][7][15] Operational Efficiency - **Cash Flow Management**: The company is enhancing accounts receivable management to alleviate credit impairment pressure, with expectations of recovering over 500 million yuan from government receivables in the next two years [3][9][14] - **Cost Control**: The company aims to reduce sales and management expenses as revenue scales up, while maintaining a focus on high-margin innovative products [27][34] Market Trends - **Birth Defects and Women's Health**: Increased government support for public health projects related to birth defects is expected to drive market growth [31] - **ICL Business Strategy**: The ICL team is focusing on high-end testing technologies and services, with plans to optimize laboratory layouts and reduce less advantageous routine testing platforms [20][23][22] Challenges and Opportunities - **Market Challenges**: The company faces challenges from the HPV procurement policy, but is focusing on cervical cancer screening and building core competencies in women's health [32] - **Long-term Growth**: Despite short-term revenue impacts, the company sees long-term growth potential in new product lines and market expansion [32][33] Conclusion - **Strategic Focus**: Cap Bio is navigating through significant industry challenges while strategically positioning itself for future growth through innovation, operational efficiency, and market expansion initiatives [34]

Financial Performance - In 2024, the company achieved operating revenue of 815.53 million yuan, a year-on-year decrease of 26.16% [2] - The net profit attributable to shareholders was -654.88 million yuan, a decline of 566.20% [2] - In Q1 2025, the operating revenue was 134.06 million yuan, down 26.78% year-on-year, with a net profit of -27.30 million yuan, a decrease of 90.21% [8] Business Challenges - The decline in revenue was primarily due to the implementation of centralized procurement for HPV-DNA testing products, leading to a decrease in factory prices [8] - Medical testing services saw a revenue drop of 38.48% in 2024, totaling 241.16 million yuan [3] - The company recorded significant impairment losses, including 608.01 million yuan in credit impairment losses and 37.75 million yuan in asset impairment losses in 2024 [3] Strategic Initiatives - The company is focusing on the "Molecular Diagnosis Products, Medical Testing Services, and Healthcare Management" strategy to drive growth [3] - In 2024, R&D investment was 102.48 million yuan, accounting for 12.57% of operating revenue, with 92 medical device registrations and 192 patents obtained [5] - The "Kepu Kang and Medical Testing 5.0 Strategy" aims to integrate resources and enhance service offerings through a network of third-party laboratories [4] Operational Improvements - The company is enhancing operational efficiency by consolidating underperforming laboratories and focusing on high-end testing services [6] - The establishment of the "Chaozhou Kepu Kang and Hospital" aims to provide specialized medical services, particularly in tumor early screening and health management [7] Future Outlook - The company anticipates improved cash flow management and a focus on receivables recovery, with approximately 500 million yuan in receivables from government contracts [8][10] - The introduction of new products, such as cervical cancer methylation testing, is expected to mitigate revenue losses from HPV product price reductions [15] - The company is optimistic about the growth potential of its personalized medicine and STD product lines, which have shown significant revenue increases [15][16]

为规范公司募集资金的管理，提高募集资金使用效率，公司根据《深圳证券 交易所创业板股票上市规则》《上市公司监管指引第 2 号—上市公司募集资金管 理和使用的监管要求》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等相关规定，结合公司的实际情况，制定了《募集资金管 理制度》。 证券代码：300639 证券简称：凯普生物 公告编号：2025-030 广东凯普生物科技股份有限公司 关于注销部分募集资金专户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意广东凯普生物科技股份有限公 司向特定对象发行股票注册的批复》（证监许可[2020]1713 号）同意，公司向包 括实际控制人之一、董事、常务副总经理管秩生先生在内的 8 名特定对象发行人 民币普通股（A 股）22,945,804 股，每股发行价格为人民币 45.76 元，募集资金 总额为人民币 105,000.00 万元，扣除发行费用后的募集资金净额为 102,741.96 万元。立信会计师事务所(特殊普通合伙)于 202 ...

广东凯普生物科技股份有限公司（以下简称"公司"）已于2025年4月29日披 露了《2024年年度报告》及摘要。为了更好地与广大投资者进行交流，使投资者 能够进一步了解公司2024年度经营情况，公司将于2025年5月9日（星期五） 15:00—17:00在同花顺路演平台（https://board.10jqka.com.cn/ir）举行2024 年度业绩说明会。本次年度业绩说明会将采取网络远程文字互动的方式举行，投 资者可登录https://eseb.cn/1ehGAXG0gLu参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：董事长管乔中先生、董事兼副总经理兼 首席科学家谢龙旭先生、独立董事陈英实先生、副总经理兼董事会秘书陈毅先生、 财务总监李庆辉先生。 投资者可以通过以下两种方式参与： 1）登录以下网址进入直播间进行提问： https://board.10jqka.com.cn/rs/pc/detail?roadshowId=1010524 证券代码：300639 证券简称：凯普生物 公告编号：2025-031 广东凯普生物科技股份有限公司 关于举行 2024 年度网上业绩说明会的公告 本公司及董事 ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for the reporting period, marking its first annual loss since listing, primarily due to industry policy adjustments and market demand changes affecting its molecular diagnostic products and medical testing services [9][10][11]. Company Overview - The company is a leading provider of integrated molecular diagnostic products and services in China, focusing on three main business segments: molecular diagnostic products, medical testing services, and healthcare services [5][7]. - It has developed a wide range of products for tumor screening, infectious and genetic disease testing, and maternal and child health management, which are widely used in clinical diagnosis and public health [5][6]. Financial Performance - The company achieved operating revenue of 815.53 million yuan, a year-on-year decrease of 26.16%, with a net profit attributable to shareholders of -654.88 million yuan, a decline of 566.20% [9][10]. - The decline in revenue was attributed to price reductions in molecular diagnostic products due to policy changes and a decrease in demand for medical testing services, leading to operational losses in these segments [10][11]. Business Development - The company has been actively promoting its HPV testing products, responding to the national initiative to eliminate cervical cancer, and has conducted numerous public awareness campaigns [12][13]. - It has established a network of 31 third-party medical laboratories across China, focusing on high-end testing technologies and expanding its service offerings [7][8]. Product Innovation - The company has invested over 860 million yuan in research and development since its inception, with a focus on enhancing its molecular diagnostic product line and obtaining various medical device certifications [18][19]. - New product developments include a range of genetic testing kits and personalized medicine solutions, which have seen increased usage and sales [16][20]. Strategic Initiatives - The company is implementing the "Kepu Kanghe Medical Testing 5.0" strategy, integrating precision medicine and health management to provide comprehensive health services [8][22]. - It is also focusing on international expansion, having obtained multiple certifications and patents in various countries, and is actively participating in international exhibitions to showcase its products [26][27]. Operational Efficiency - The company is taking measures to reduce costs and improve operational efficiency in its medical laboratory segment, including optimizing laboratory operations and consolidating facilities [28][31]. - It has also adjusted its workforce structure to enhance productivity, with a significant reduction in personnel costs planned for the upcoming year [33][34].

证券代码：300639 证券简称：凯普生物 公告编号：2025-029 （三） 主要会计数据和财务指标发生变动的情况及原因 适用 □不适用 1、资产负债表项目变动原因（单位：元） | 项目 | 2024 年 3 月 31 日 | 2023 年 12 月 31 日 | 增减变化率 | 变化原因 | | --- | --- | --- | --- | --- | | 应收票据 | 6,734,842.92 | 4,251,369.70 | 58.42% | 主要系尚未到期的应收票据增加 | | | | | | 所致。 | | 一年内到期的非流动 | 4,839,791.22 | 7,905,324.29 | -38.78% | 主要系一年内到期的租赁费用减 | | 负债 | | | | 少所致。 | | 其他流动负债 | 4,280,469.83 | 1,009,578.01 | 323.99% | 主要系增值税税率上升导致合同 | | | | | | 履约义务税金增加所致。 | | 长期借款 | 97,787,539.34 | 52,787,539.32 | 85.25% | 主要系凯普医学科学园专项借款 | ...

一、主要会计数据和财务指标 前十大流通股东累计持有： 29674.5万股，累计占流通股比： 46.71%，较上期变化： -413.78万股。 | 持有数量(万股) 名称 | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 香港科技创业股份有限公司 | 19319.83 | 30.42 | 不变 | | 云南众合之企业管理有限公司 | 4014.76 | 6.32 | 不变 | | 深圳国调招商并购股权投资基金合伙企业(有限合 | | | | | 伙) | 3076.57 | 4.84 | 不变 | | 云南炎辰企业管理有限公司 | 1463.75 | 2.30 | 不变 | | 北京新维港科技有限公司 | 381.34 | 0.60 | 189.50 | | 赵雪芳 | 330.03 | 0.52 | 19.40 | | 祁玉峰 | 317.30 | 0.50 | 不变 | | 龙喜福 | 317.11 | 0.50 | 新进 | | 王建瑜 | 273.44 | 0.43 | 不变 | | 香港中央结算有限公司 | 180.3 ...

证券代码：300639 证券简称：凯普生物 公告编号：2025-016 2025 年第一季度报告披露提示性公告 广东凯普生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 董事会 2025 年 4 月 29 日 广东凯普生物科技股份有限公司《2025 年第一季度报告》已于 2025 年 4 月 29 日 在 中 国 证 监 会 指 定 的 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （http://www.cninfo.com.cn/）上披露，请投资者注意查阅。 特此公告。 广东凯普生物科技股份有限公司 ...